RGEN News and Press, Repligen Corporation From 11/05/20

Repligen (RGEN): Q3 Non-GAAP EPS of $0.40; GAAP EPS of $0.27 beats by $0.11.Revenue of $94.06M (+35.4% Y/Y) beats by $7.61M.Press Release For further details see: Repligen EPS beats by $0.11, beats on revenue

Reports record quarterly revenue of $94.1 million with strong margin expansion Overall revenue grew 35% year-over-year, with organic growth of 31% Raises revenue guidance to $ 348 -$ 352 million and overall revenue growth to 29%-30% for full...

- Webcast and Conference Call to Be Held Thursday, November 5, 2020 at 8:30 a.m. EST - WALTHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2020 financial results on Thursday, November 5...

Repligen (RGEN) and Navigo Proteins GmbH have developed a novel affinity ligand targeting the spike protein that can be used to purify COVID-19 vaccines.The companies are scaling up manufacturing and developing the related affinity chromatography resin (high purity capture of the molecule).Th...

WALTHAM, Mass. and HALLE (Saale), Germany, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in n...

Repligen is a investment on the overall growth of the most exciting portion of the biotech industry without exposure to the full risks of the of drug approval process. COVID has a overall effect of increasing demand for Repligen products that helps make the vaccines and therapeutic dr...

Repligen hasn't seen quite the same tailwind from COVID-19 as some of its larger, more diversified rivals, but pandemic-related product development is still adding about 10% to sales. Product portfolio expansion, capacity expansion, market share gains, and underlying market growth are...

In this episode of Rule Breaker Investing : Review-a-palooza! Motley Fool co-founder David Gardner is joined by Motley Fool analyst Joey Solitro to review two previous five-stock samplers to find out how they are doing relative to the market. Solitro also shares his own experience with COVI...

Three very different stocks, but all with the kind of long-term earnings potential that growth investors look for: Industrial software company PTC (NASDAQ: PTC) is a play on the fourth industrial revolution, wind blade manufacturer TPI Composites (NASDAQ: TPIC) benefits from growth in th...

At a time when many businesses have been impacted by the financial consequences of the coronavirus pandemic, Repligen (NASDAQ: RGEN) continues to hum along. The bioprocess engineering leader reported record quarterly revenue and profitability in the Q2 2020, and management raised full-year 2...